Empowering Cell Therapies
At ImmunoShield, we develop technologies that utilize cell therapies to find a longer-term solution in treating Type 1 Diabetes.
What is ImmunoShield Therapeutics?
The bridge for cell therapies to become impactful long-term treatments and so much more…
ImmunoShield is building an enabling platform for allogeneic cell therapy that is designed to protect therapeutic cells and support long-term function after implantation. Rather than relying on broad immune suppression to protect implanted cells from immune destruction, ImmunoShield is built around the idea that precision matters: the best therapies should work with biology in a way that is selective, durable, and clinically meaningful.
The Real Impact
Cell therapies can transform the treatment of chronic diseases like type 1 diabetes, with stem cell-derived insulin-secreting cells potentially providing long-term biological insulin delivery. However, many of these types of therapies still face the same core obstacle: the body destroys or disables the implanted cells, and patients must take dangerous immune suppressive drugs to avoid this. The potential of cell therapy replacement has become increasingly clear, but the issues severely limit broader clinical adoption.
Our Approach
ImmunoShield is solving the translational bottlenecks that stand between breakthrough biology and real-world treatment. Our focus is on building the technology layer that complements and strengthens therapeutic programs rather than creating another full-stack program ourselves. By critically analyzing and learning from previous attempts at delivering insulin-secreting cells in a clinical setting, we’re confident that our technology can succeed in delivering these therapies by improving protection, persistence, and practicality.
Keep Up with the Industry
In the world of cell therapies there is always something new to learn and discover.
Follow along with the ImmuoShield Therapeutics and discover along side the experts and industry leaders.